# Arcturus Therapeutics Holdings Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Arcturus Therapeutics Holdings Inc.).

## Overview

Arcturus Therapeutics Holdings Inc. is a U.S.-based biotechnology company focused on developing mRNA medicines and vaccines using its proprietary LUNAR delivery platform and self-amplifying RNA technology. The company’s pipeline includes therapeutic candidates for rare diseases and infectious diseases, alongside partnered vaccine programs with large pharmaceutical and government collaborators. Arcturus has not yet built a broad commercial product business; instead, it monetizes through collaboration payments, research and development funding, milestones, and government contracts. Its most visible commercialized asset is KOSTAIVE, an mRNA COVID-19 vaccine approved in Japan and Europe through partnered arrangements. The business is therefore a development-stage RNA platform company whose value depends on clinical progress, regulatory approvals, manufacturing scale-up, and partner execution.

## Products & services

• Self-amplifying mRNA vaccine and therapeutic platform
• LUNAR lipid nanoparticle delivery technology
• ARCT-032 for cystic fibrosis
• ARCT-810 for OTC deficiency
• ARCT-154 / KOSTAIVE COVID-19 vaccine program
• ARCT-2304 seasonal influenza vaccine candidate
• Contract development and manufacturing support via ARCALIS

- **mRNA therapeutics** (35%) — Clinical-stage RNA medicines for rare diseases and other therapeutic indications.
- **mRNA vaccines** (30%) — Self-amplifying mRNA vaccine candidates and partnered vaccine programs for infectious diseases.
- **Platform technology and delivery** (20%) — LUNAR lipid nanoparticle delivery and related enabling technology licensed to partners.
- **Collaboration and government funding** (10%) — R&D funding, milestones, upfront payments, and cost reimbursement from partners and agencies.
- **Manufacturing services** (5%) — mRNA manufacturing and process support through the ARCALIS joint venture.

- Self-amplifying mRNA vaccine and therapeutic platform
- LUNAR lipid nanoparticle delivery technology
- ARCT-032 for cystic fibrosis
- ARCT-810 for OTC deficiency
- ARCT-154 / KOSTAIVE COVID-19 vaccine program
- ARCT-2304 seasonal influenza vaccine candidate
- Contract development and manufacturing support via ARCALIS

## Customers

Arcturus primarily sells to pharmaceutical partners, public-sector agencies, and research collaborators rather than to end consumers. Its revenue comes from collaboration agreements with companies such as CSL Seqirus and Vinbiocare, where partners pay for technology access, development support, and future commercial rights. The company also receives funding from BARDA, reflecting demand from government buyers for pandemic preparedness and countermeasure development. In Japan, ARCALIS and partner Meiji Seika Pharma support commercial manufacturing for KOSTAIVE, showing that some customers are downstream pharma manufacturers and distributors. Because Arcturus is still largely pre-commercial, customer demand is tied to clinical milestones, regulatory progress, and manufacturing readiness rather than routine product replenishment.

- **Pharmaceutical collaboration partners** (primary) — Companies such as CSL Seqirus and other biotech/pharma partners pay for technology rights, development services, milestones, and potential commercial access.
- **Government and public health agencies** (primary) — Agencies such as BARDA fund vaccine and countermeasure development to support pandemic preparedness and response capabilities.
- **Manufacturing and commercialization partners** (secondary) — Partners such as Meiji Seika Pharma and ARCALIS use Arcturus technology and manufacturing support to produce and commercialize approved vaccines.
- **Biotech licensees and technical support customers** (secondary) — Organizations like Vinbiocare buy technical expertise and support to build mRNA manufacturing capabilities and advance clinical obligations.
- **Research collaborators and foundations** (secondary) — Disease-focused groups and collaborators support early-stage programs and help fund preclinical and clinical development.

- Pharmaceutical partners buying platform access, development support, and licenses
- Government agencies funding pandemic preparedness and vaccine development
- Biotech collaborators seeking mRNA expertise and manufacturing know-how
- Downstream vaccine manufacturers and distributors in partnered markets
- Research and clinical collaborators supporting trial execution and data generation

## Geography

Arcturus is headquartered in the United States, but its business is structurally international because its partners, clinical programs, and manufacturing footprint span multiple regions. Japan is strategically important through the ARCALIS joint venture, which was built to manufacture mRNA drug substance and drug product and now supports commercial production for KOSTAIVE. Europe is also relevant because KOSTAIVE has received approval there, expanding the company’s partnered commercial footprint beyond the U.S. The company’s revenue exposure is driven more by partner and regulatory geography than by direct consumer sales, so market access depends on approvals, local manufacturing, and country-specific public health procurement. This makes execution in Japan, Europe, and the U.S. especially important to future commercialization and funding.

- Headquartered in the United States and listed as a U.S. biotech company
- Japan is a key operating base through the ARCALIS manufacturing joint venture
- KOSTAIVE commercial manufacturing and shipment are underway in Japan
- Europe matters because KOSTAIVE has received regulatory approval there
- U.S. government funding and clinical development remain central to the pipeline
- Vietnam has been part of prior technology transfer and support arrangements

## Strategy

Arcturus’ strategy is to convert its RNA platform into partnered and eventually commercial products while limiting capital intensity through collaborations and government funding. A major priority is advancing clinical programs such as ARCT-032 and ARCT-810 to prove that the platform can work beyond vaccines and into rare disease therapeutics. The company is also using partnerships like CSL Seqirus and BARDA to offset development costs, broaden validation, and gain access to commercial channels. Manufacturing scale-up is another strategic pillar, with ARCALIS intended to provide mRNA drug substance and drug product capacity for both Arcturus and third parties. Overall, the strategy is to build optionality across therapeutics, vaccines, and manufacturing while reducing dependence on any single program.

- **Advance ARCT-032 and ARCT-810 through clinical development** (short-term) — Clinical proof-of-concept is essential to show the platform can create value in therapeutic indications beyond vaccines.
- **Commercialize partnered vaccine programs** (medium-term) — Approved products can generate milestones, royalties, and validation of the self-amplifying RNA platform.
- **Scale manufacturing and supply chain capability** (medium-term) — Reliable mRNA manufacturing is a prerequisite for clinical supply, regulatory approval, and commercial launch.
- **Secure non-dilutive funding and strategic collaborations** (short-term) — Partner and government funding helps finance development in a capital-intensive industry with long timelines.

- Advance clinical-stage programs to validate the platform in rare disease and infectious disease
- Use partnerships to fund development and reduce cash burn
- Expand commercial reach through collaborators rather than building a large direct sales force
- Scale mRNA manufacturing through ARCALIS to support future supply needs
- Leverage BARDA and other public funding for pandemic preparedness programs
- Pursue regulatory approvals that can create milestone and royalty revenue

## Risks

Arcturus faces the classic risks of a development-stage biotech company: clinical failure, regulatory delay, and the possibility that product candidates never reach commercial scale. The company has limited operating history, no broad product-sales base, and ongoing dependence on collaboration and grant revenue, so any slowdown in partner activity or government funding can materially affect cash flow. Manufacturing scale-up is a major risk because mRNA production and stability requirements are complex, and unresolved process issues can delay trials or approvals. The company also faces intense competition from larger biopharma firms and other RNA platform developers with greater capital, manufacturing capacity, and commercial infrastructure. In addition, public-sector exposure creates sensitivity to government budget cycles, shutdowns, and policy changes, while foreign operations add execution and regulatory risk in Japan and other markets.

- **Clinical development failure** [high] — The company’s value depends on proving safety and efficacy in programs such as ARCT-032 and ARCT-810.
- **Manufacturing and scale-up issues** [high] — mRNA drug substance and drug product manufacturing is technically complex and can delay trials or commercialization.
- **Funding and liquidity dependence** [high] — The company relies on collaboration payments, grants, and capital raises rather than product sales.
- **Competitive pressure in RNA therapeutics and vaccines** [medium] — Larger biotech and pharma companies can outspend Arcturus on R&D, trials, and commercialization.
- **Government funding and policy disruption** [medium] — BARDA and other public-sector programs are sensitive to budget, shutdown, and procurement changes.

- Clinical trial failure or delay could eliminate value from key pipeline assets
- Regulatory setbacks could postpone approvals and reduce milestone revenue
- Dependence on collaboration and grant revenue creates funding volatility
- Manufacturing scale-up issues could delay supply, trials, or commercialization
- Competition from larger RNA and vaccine developers is intense
- Government shutdowns or policy changes can disrupt BARDA-related work
- Foreign partner and manufacturing execution risk is meaningful in Japan and other markets

## Accounting

Arcturus’ accounting is heavily shaped by collaboration and grant arrangements, so revenue recognition depends on identifying performance obligations, allocating consideration, and determining when control transfers. Because the company receives upfront payments, milestone fees, research funding, and cost reimbursements, reported revenue can fluctuate materially from quarter to quarter based on partner progress rather than product demand. The BARDA contract and similar arrangements require judgment around reimbursable costs, deferred revenue, and the timing of revenue earned versus cash received. Research and development accruals are also important because clinical and manufacturing costs are incurred before invoices are finalized, which can move operating expenses between periods. As with many biotech companies, stock-based compensation, lease assumptions, and valuation estimates for options and contingent liabilities can also materially affect reported results.

- **Collaboration and grant revenue recognition** — Affects reported revenue, deferred revenue, and comparability across quarters.
- **Research and development accruals** — Affects operating expenses and accrued liabilities.
- **Stock-based compensation** — Affects operating expense and non-cash dilution analysis.
- **Contingent and contractual liabilities** — Affects accrued expenses and cash flow timing.

- Revenue recognition for collaboration, license, milestone, and reimbursement contracts
- Deferred revenue and contract liabilities from upfront partner payments
- R&D accruals tied to clinical, manufacturing, and regulatory spending
- Quarterly revenue volatility driven by milestone timing rather than product sales
- Stock-based compensation and option valuation assumptions
- Lease and borrowing-rate estimates that affect balance sheet and expense recognition

---

*Last updated: 2026-08-11T04:46:21.282301+00:00*